VolitionRx presents Capture-Seq technology with 95% early-stage cancer detection
AI Summary- VolitionRx presented its Capture-Seq technology at ESMO MAP 2026.
- Capture-Seq detected 95% of stage I and II cancers in validation studies.
- The method uses liquid biopsy for early-stage cancer detection.